Rapacuronium bromide

Rapacuronium bromide (brand name Raplon) is a rapidly acting, non-depolarizing aminosteroid neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.

Rapacuronium bromide
Rapacuronium bromide
Clinical data
Other names[(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration
    Intravenous
    ATC code
    • none
    Legal status
    Legal status
    • US: Withdrawn
    Pharmacokinetic data
    BioavailabilityNot applicable
    Protein bindingVariable
    MetabolismHydrolyzed to active metabolites
    CYP system not involved
    Elimination half-life141 minutes (mean)
    ExcretionRenal and fecal
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.211.226
    Chemical and physical data
    FormulaC37H61N2O4+
    Molar mass597.891 g/mol g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.[1]

    References

    1. Shapse, Deborah (March 27, 2001). "Voluntary Market Withdrawal" (PDF). (10.8 KiB). Organon International. Retrieved on 2007-04-02.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.